Brief: Aardvark Therapeutics Plans To Unblind Hero And Ole Data To Inform Path Forward Following FDA Clinical Hold
14/05/2026 21:18
May 14 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS PLANS TO UNBLIND HERO AND OLE DATA TO INFORM PATH FORWARD FOLLOWING FDA CLINICAL HOLD AARDVARK THERAPEUTICS INC - FDA PLACES FULL CLINICAL HOLD ON AARDVARK'S IND FOR ARD-101 AARDVARK THERAPEUTICS INC - CLINICAL HOLD APPLIES TO ALL ONGOING PHASE 3 HERO AND OLE TRIALS FOR ARD-101 AARDVARK THERAPEUTICS INC - TO UNBLIND HERO AND OLE TRIAL DATA FOR ARD-101 FOR ASSESSMENT, DETERMINE NEXT STEPS FOR THE ARD-101 PROGRAM Source text: ID:nGNXJdz8k Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark